Egrifta and Breastfeeding

In animal studies on Egrifta (tesamorelin) and breastfeeding, the offspring suffered serious side effects. As a result, the manufacturer recommends that women avoid breastfeeding when taking this drug. This aligns with the CDC recommendation that U.S. women with HIV avoid breastfeeding in order to prevent possibly transmitting the virus to their infants.

Can Breastfeeding Women Take Egrifta?

At this time, it is unknown if Egrifta™ (tesamorelin acetate) passes through breast milk in humans. Animal studies showed that using Egrifta while breastfeeding caused serious side effects in the offspring. The manufacturer recommends that women who take this medication not breastfeed.
More importantly, the Centers for Disease Control and Prevention (CDC) recommends that mothers in the United States who are infected with human immunodeficiency virus (HIV) not breastfeed. The HIV virus can pass through breast milk, possibly leading to transmission to the infant.

Talking With Your Healthcare Provider

You should discuss breastfeeding and Egrifta with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.
Baby Milestones You've Never Heard Of

Egrifta Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.